Clinical Trials Directory

Trials / Conditions / Neovascular (Wet) Age-Related Macular Degeneration

Neovascular (Wet) Age-Related Macular Degeneration

13 registered clinical trials studyying Neovascular (Wet) Age-Related Macular Degeneration — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal V
NCT07501052
Sam Chun Dang Pharm. Co. Ltd.Phase 2
CompletedA Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitrea
NCT07484074
Ollin Biosciences, Inc.Phase 1
Not Yet RecruitingThe Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Dege
NCT06759597
Assiut University—
Active Not RecruitingSwitch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT07390253
Vienna Institute for Research in Ocular Surgery—
RecruitingA Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600
Skyline Therapeutics—
TerminatedA Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized
NCT05473715
BayerPhase 4
Active Not RecruitingRecurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
NCT06717139
St. Erik Eye Hospital—
CompletedEfficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
NCT05439629
Bio-Thera SolutionsPhase 3
CompletedReal-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet)
NCT06184360
Novartis Pharmaceuticals—
Recruiting4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
NCT05197270
4D Molecular TherapeuticsPhase 1 / Phase 2
CompletedSafety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneratio
NCT04126317
Regeneron PharmaceuticalsPhase 2
CompletedA Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration
NCT04857177
Chong Kun Dang PharmaceuticalPhase 3
CompletedObservation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
NCT04847895
Novartis Pharmaceuticals—